POCL Enterprises (539195)

FairStock Score: 63/100 — STEADY

Score breakdown: P/E: 2/3 · ROCE: 2/2 · Growth: 2/2 · Dividend: 0/1

Key Financials

Strengths

• ROE of 48.11% and ROCE of 32.43% indicate outstanding capital efficiency.
• P/E of 14.57 against 55.08% profit growth gives PEG of 0.47, attractive on an earnings basis.
• Piotroski F-Score of 7/9 suggests solid fundamentals across profitability, leverage, and efficiency.
• Sales grew 6.83% while profits grew 55.08%, demonstrating strong operating leverage.

Concerns

• P/B of 19.72 versus book value of ₹28.25 leaves no margin of safety.
• Latest quarter net profit of ₹9 Cr is far below the trailing annual run-rate of roughly ₹109 Cr implied by the P/E, signaling possible earnings deterioration.
• Debt/Equity is not available, so leverage risk cannot be properly assessed.
• Dividend yield of only 0.36% is negligible, and the 52-week range of ₹142 to ₹557 highlights cyclicality and volatility.

AI Analysis

When I look at POCL Enterprises, the first thing that catches my eye is the contrast between the income statement and the balance sheet. The company earns a superb 48.11% return on equity and 32.43% return on capital employed. At ₹557, the P/E is 14.57 and the PEG is only 0.47 against 55.08% profit growth. That sounds like a wonderful compounding machine. But Ben Graham taught me to weigh every number against price. At ₹557, the market values the firm at ₹1,584 crore, while book value is just ₹28.25 per share—so I am paying 19.72 times book. That leaves no margin of safety, and in a commodity chemicals business, such rich multiples can be dangerous. Sales growth is only 6.83%, so the impressive profit growth is not coming from strong demand; it is more likely operating leverage, price spikes, or cost gains. The last quarter worries me: net profit of ₹9 crore on sales of ₹364 crore, compared with a trailing P/E that implies around ₹109 crore of annual profit. Either there is sharp seasonality, or earnings are rolling over. The 52-week range of ₹142 to ₹557 shows this is a volatile cyclical, not a steady compounder. A 0.36% dividend yield offers little compensation while I wait. I am not saying there is no value; the Piotroski score of 7/9 and low PEG say the business is healthy on some measures. But in a commodity chemical, today's low P/E can become tomorrow's high P/E when margins revert. If I buy here, I am betting on continued cyclical strength and execution. I would rather wait for a better price and clearer quarterly earnings momentum.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer